Takeaway: global r&d budget into the top 10 medical equipment company

Global r&d budget into the top 10 medical equipment company

Company: the company

Headquarters: new Brunswick, New Jersey in the United States

In fiscal spending on research and development: $7.5 billion

Priorities and projects: in 2010, Johnson &johnson's research and development costs from $2009 in 7 billion fell to $6.8 billion, slightly, but in 2011 the company's r&d and back up to $7.5 billion. Johnson & Johnson in North America and Europe have research and development institutions, in addition, the research and development institutions also throughout Israel, Japan, Singapore, India and other countries. In fact, last summer, the company also opened an innovation center in China, is used to design and development for Asian emerging markets - mainly China and India medical devices and diagnostic products. In 2011, Johnson & Johnson and its subsidiaries related to the cooperation agreement signed a series of instruments. Late last year, for example, Metamark Genetics and Janssen Biotech agreement, mutual recognition and characterization plays a decisive role in tumor progression and diffusion of specific targets for cancer. In addition, once the Johnson & Johnson finished to Cindy (Synthes) acquisition, orthopedic products will be further growth.

Announced this year, Johnson & Johnson Ortho - Clinical Diagnostics and cooperative development Avioq Avioq HTLV - I/II Microelisa System testing, when used for blood screening and organ donation to detect T lymphocyte antibody of type I and type II virus. If not checked out this kind of antibody, is likely to lead to a rare white disease disease and neural system disease. In addition, the subsidiary Veridex in published research report, are likely to develop a test that can determine the risk of heart attack patients. Veridex said last year, will work with the United States at the Massachusetts General Hospital, Massachusetts General Hospital), cooperation, development and commercialization of the next generation of circulating tumor cells technology, to capture, technology and characterization of patients with tumor cells found in the blood. In the next few years, the company's projects will still be many, including the United States and Japan Incraft AAA bracket of transplant program; Used to detect the next generation of real-time inspection of diabetes (point - of - care) system; The next generation of hip and shoulder joint products. As well as many diagnostic reagents project.

Abbott launched in 2011 FreeStyle InsuLinx, diabetes diagnostic products

Company: abbott laboratories

Headquarters: abbott park, Illinois in the United States

In fiscal spending on research and development: $4.1 billion

Priorities and projects: since 2010, when the development costs for abbott laboratories in 2009 from $2.7 billion to $2.7 billion, 2011, the company's research and development costs and continue to jump to $4.1 billion. However, abbott laboratories and list of other companies is a bit different, because it is also a pharmaceutical and nutritional products manufacturers. In fact, the company in the annual report pointed out that its development costs are mostly used for exclusive rights to pharmaceutical products. For example, the company in blood products and diagnostic products respectively in 403 million and 325 million research and development costs.

Abbott lists some of the current products being developed by blood vessels. The company expects this year or next year, its next generation of drug-eluting stents (des) Xience Xpedition access to the us and European regulatory approval. The company is also seeking approved in the United States new coronary artery and intravascular catheter, and used in the iliac artery disease Absolute Pro and Omnilink Elite stents. Although for abbott, already has a large number of cardiovascular products, but the company also is developing ophthalmic products, and some research projects, including: in 2009 by buying Visiogen received the Synchrony of intraocular lens (intraocular lens) and intraocular lens implantation system. In terms of molecular diagnostics, the company is developing a series of tumor and infectious disease detection reagent. In terms of diabetes, abbott is updating hospital blood glucose monitoring system, and hope to apply to the regulatory submission for next year.

Abbott announced last year, it will be split into two listed companies: keep abbott name medical products company and named AbbVie drug companies.

Siemens development with RFID chip bags, ensure that blood to maintain low temperature in the transportation

Company: Siemens medical

Headquarters: Frankfurt, Germany

In fiscal spending on research and development: $1.56 billion

Key and project: as part of the German giant Siemens (Siemens) its, Siemens medical (Siemens Healthcare) in fiscal 2011 revenue of $16.3 billion, but only invested $1.56 billion in research and development costs. Siemens medical has more than 51000 employees, its business covers widely, including imaging and treatment system, clinical products and listening devices. But Siemens from last autumn ongoing two-year, vaguely called "agenda 2013" restructuring plan, the purpose is to promote innovation, layoffs, "reset" radiotherapy department of business and the business is concentrated in the areas such as diagnosis, in order to help reduce health care costs.

Years, some new research and development project is expected to put into practice, such as announced and Maquet, reaching an agreement to jointly develop the diagnosis and surgery of integrated system is used to compound the operating room. The company stressed that it is developing can detect indicator of alzheimer's disease amyloid plaque diagnostic tool. Siemens medical also in the development of Biograph mCT PET - CT scanners; In addition, quantitative software used to enhance amyloid plaques PET scan is seeking 510 (k) for approval. Amyvid in addition, the company will be the production and marketing, this is Lilly (Eli Lilly) approved by FDA, used to detect patients with beta amyloid plaques in the brain of the new type of developer, can evaluate patients suffering from alzheimer's disease or other related diseases.

The most advanced cardiac pacemaker medtronic InSync III, for damaged ventricular resynchronization

Company: medtronic

Minneapolis headquarters: the United States

In fiscal spending on research and development: $1.51 billion

Key and project: although medtronic is restructuring, and downsizing 2000 to solve the problem of slow growth, but the Minnesota medical equipment giant r&d is still slow but steady increase in recent years, the 2010 and 2009, the r&d investment of $1.46 billion and $1.35 billion respectively. The budget cuts, in turn, help the company in such as the Solera system and used for atrial fibrillation, the Arctic Front spinal cord cryoballoon. Medtronic says, it not only takes the new innovation, but also to improve the listed products and expand their indications. Which is mentioned in the us healthcare reform that need to be the priority to the development of content: the development can help reduce the patients' medical expenses and hospitalization time of equipment. Therefore, medtronic has been committed to develop artificial pancreas for patients with diabetes, it can be brought into the pacemaker of MRI (magnetic resonance imaging (MRI) - friendly pacemaker) MRI SureScan Revo approved in the United States (the first such products) and used in the treatment of epilepsy and other neurodegenerative diseases of deep brain stimulation products has received FDA approval.

For a long time, GE healthcare has been the medical equipment innovation leader, its products include portable ecg monitoring equipment

GE healthcare company:

Headquarters: Britain

In fiscal spending on research and development: $1.3 billion

Priorities and projects: have a look at GE healthcare for its parent company, general electric (GE) what it means: last year, GE's research and development costs $4.6 billion, which is used for GE medical for $1.3 billion. The money than the last fiscal year rose 7%, also make GE medical research and development budget into the global top ten list. GE healthcare, according to its r&d plan into diagnosis business (including genome sequencing and molecular diagnosis), healthcare IT business and life science. Alzheimer's one area of particular concern is the company; GE medical is developing flutemetamol imaging agent, the product can improve the probability of alzheimer's disease this fatal neurodegenerative disease diagnostic ability. Last fall, the company also announced that by 2020, plans to invest $1 billion in total value of the research and development budget for cancer research, including diagnosis and treatment of new products. Don't forget, GE healthcare in conducting a five-year project began in 2010, the project plans to invest $3 billion, to find new method can reduce the cost of medical care.

Company: philips health care

Headquarters: andover, Massachusetts in the United States

In fiscal spending on research and development: $967 million

Key and projects: the Dutch consumer products giant in fiscal year 2011 for its health care department invested $967 million in research and development costs, than the $2010 in 912 million and $2009 in 887 million. In 2011, according to the company's annual report, its research and development spending is mainly used in three business segments: imaging system, patient care and clinical informatics.

Philips also advances into emerging markets. For example, in June last year, the company has struck a deal with Russia ROSATOM, authorized the latter three nuclear medical imaging system. In November, the company's first commercial Ingenuity TF PET/MR whole-body PET/MRI system 510 (k) permission. In Germany, the company is working with the German Federal Education department (Federal Ministry of Education and Research, BMBF) cooperation, the development of the whole body magnetic particle imaging system and combined with the MPI and MRI technology preclinical composite system.

Company: Baxter

Headquarters: Illinois field of John Deere

In fiscal spending on research and development: $946 million

Priorities and projects: Baxter consists of three business units: medical equipment, pharmaceutical and biotechnology, its all product research and development is the internal research and development, at the same time, through the acquisition of companies to enhance research and development ability. Company goal: to strengthen including kidney disease, the immune system of patients with hemophilia disease and trauma these key areas of business. For example, in 2011, Baxter target domain including approval of ARTISS fibrin glue extension indications, used for bonding tissue flap in plastic surgery. The company also is developing a new home hemodialysis system, used in the treatment of patients with end-stage renal disease. In 2011, the company said in its annual report, early last year, it established the Baxter Ventures, for some development with the company's strategic focus is to invest in the early stages of the company, the investment amount more than $200 million. At the end of 2011, the company also carried out a large acquisition, for $325 million acquisition of Synovis Life Technologies, got the latter for obesity and vascular surgery, hernia repair, cardiac abnormalities and brain repair surgery and other biological and mechanical products.

Boston scientific's TruePath CTO is used in the treatment of chronic totally occluded lesion

Company: Boston scientific

Headquarters: Massachusetts"

In fiscal spending on research and development: $895 million

Priorities and projects: 2011, Boston scientific though focus on its core business, but still looking for new opportunities. In fact, the company on its web site that its mission is in minimally invasive treatment instrument on "Delivering What 's Next", saying it on r&d investment ratio more than most of the medical device field. However, the company on r&d investment last year compared with the past two years, still slightly reduce: r&d spending $2011 in 895 million, $939 million in 2010, just over $1 billion in 2009. Relative to 2010, the company's r&d spending has fallen by about 5%, the reason is that it's in many ways, including no longer invest on nerve vascular business, associated with the restructuring plan and cost reduction. In spite of this, the company's r&d spending in 2011 still accounts for 12% of net sales. In addition, the company in structural heart disease, atrial fibrillation, peripheral vascular and 4 acquisition field of deep brain stimulation. In neuromodulation on business, for example, the company is ready to use in Europe next year Vercise deep brain stimulation system VANTAGE research for the treatment of Parkinson's disease.

But don't expect Boston science can only rely on its internal r&d strength; The company will continue to make acquisitions in ophthalmic products and technology, in order to better provide customers with products. In march of this year, for example, Boston scientific exercise of an option for a long time, once Cameron Health S - ICD to gain FDA approval, will take the down payment of $150 million, total more than $1 billion acquisition of the defibrillator manufacturer. In addition, the company will also work with global scientific research institutions, institutions of higher learning and clinical institutions cooperation to develop and test the products. In 2011, Boston scientific increased its r&d investment in the outside the United States, such as crowns MEL announced plans in Ireland (Clonmel, Ireland) research and development institutions to invest 37 million, used to develop the next generation of cardiac rhythm management system.

Company: covidien medical care

Headquarters: Massachusetts Mansfield (Mansfield, MA), and Dublin, Ireland

In fiscal spending on research and development: $554 million

Priorities and projects: covidien medical research and development spending in fiscal year 2011 than last year rose by $100 million,. The company annual report says the growth is largely due to the medical equipment department spending caused by large number of acquisitions in 2010. Covidien medical for $2010 in 2.6 billion, for example, acquired ev3, won the new blood vessels products and clear system in the vascular repair airbag, plaque and ducts in key areas such as research project. That year, covidien medical also paid $250 million for Somanetics, won the brain and the body's blood oxygen saturation technology. Covidien to continue the trend of its acquisition in 2011, spending $325 million for BARRX that dominate, the latter is developed using endoscopic removal of precancerous minimally invasive Medical equipment development co., LTD.

Covidien medical transfer to emerging markets will also be part of r&d. Established in Shanghai in September last year, it announced a China covers an area of 10 square feet of research and development center, the center plan will be fully operational in July this year, key development for China and other emerging markets a new type of medical instrument and surgical items. The center includes laboratory and simulating the operating room, where clinical doctors and surgeons can participate in design and development of new products.

Company: green di company

Headquarters: franklin lakes, New Jersey in the United States

In fiscal spending on research and development: $476 million

Key and project: green di company to its medical surgery, diabetes care products and is famous for its fault diagnosis system. In fiscal year 2011, the company's r&d investment funds of $476 million, accounting for 6.1% of the total, compared with $2010 in fiscal 431 million and a slight increase to $2009 in fiscal 405 million. R&d spending in 2011, with $9 million for termination of a diagnostic system of research projects. To remove the cost, compared to the rest of the research and development spending a year there is still a healthy growth. Brigitte, according to the company's annual report, the company's r&d to develop new products and platforms, including 9 BD Max and BD molecular diagnostic system.

These new technologies to promote the green di company to further expand its molecular diagnostic products business. In 2011, the company in the diagnosis of department (BD Diagnostics) and British Lab21 cooperation, to develop on BD Max system using Aspergillus (Aspergillus) diagnostic reagents. In late November, the company used with BD Max of methicillin-resistant s. aureus (MRSA) bacteria diagnostic reagents obtained the CE certification, to achieve the major advances in diagnosis of MRSA infection. Green di company also through acquisitions to expand the company's development projects. In 2009, the company acquired Accuri Cytometers, the latter is used to study the personnel's personal flow cytometry instrument development and manufacturers, the purchase amount not disclosed.